[go: up one dir, main page]
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Among authors: heerspink hjl. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Empagliflozin in Patients with Chronic Kidney Disease.
Neuen BL, Fletcher RA, Heerspink HJL. Neuen BL, et al. Among authors: heerspink hjl. N Engl J Med. 2023 Jun 15;388(24):2300. doi: 10.1056/NEJMc2301923. N Engl J Med. 2023. PMID: 37314720 No abstract available.
The authors reply.
Heerspink HJL, Jongs N, Neuen BL. Heerspink HJL, et al. Kidney Int. 2023 Sep;104(3):617-618. doi: 10.1016/j.kint.2023.06.004. Kidney Int. 2023. PMID: 37599020 No abstract available.
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Nuffield Department of Population Health Renal Studies Group, et al. Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6. Lancet. 2022. PMID: 36351458 Free PMC article.
Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium.
Inker LA, Grams ME, Levey AS, Coresh J, Cirillo M, Collins JF, Gansevoort RT, Gutierrez OM, Hamano T, Heine GH, Ishikawa S, Jee SH, Kronenberg F, Landray MJ, Miura K, Nadkarni GN, Peralta CA, Rothenbacher D, Schaeffner E, Sedaghat S, Shlipak MG, Zhang L, van Zuilen AD, Hallan SI, Kovesdy CP, Woodward M, Levin A; CKD Prognosis Consortium. Inker LA, et al. Am J Kidney Dis. 2019 Feb;73(2):206-217. doi: 10.1053/j.ajkd.2018.08.013. Epub 2018 Oct 19. Am J Kidney Dis. 2019. PMID: 30348535 Free PMC article.
Trends and perspectives for improving quality of chronic kidney disease care: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Eckardt KU, Delgado C, Heerspink HJL, Pecoits-Filho R, Ricardo AC, Stengel B, Tonelli M, Cheung M, Jadoul M, Winkelmayer WC, Kramer H; Conference Participants. Eckardt KU, et al. Among authors: heerspink hjl. Kidney Int. 2023 Nov;104(5):888-903. doi: 10.1016/j.kint.2023.05.013. Epub 2023 May 26. Kidney Int. 2023. PMID: 37245565 Free article.
A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.
Selvarajah V, Robertson D, Hansen L, Jermutus L, Smith K, Coggi A, Sánchez J, Chang YT, Yu H, Parkinson J, Khan A, Chung HS, Hess S, Dumas R, Duck T, Jolly S, Elliott TG, Baker J, Lecube A, Derwahl KM, Scott R, Morales C, Peters C, Goldenberg R, Parker VER, Heerspink HJL; study investigators. Selvarajah V, et al. Among authors: heerspink hjl. Kidney Int. 2024 Aug 30:S0085-2538(24)00629-X. doi: 10.1016/j.kint.2024.08.023. Online ahead of print. Kidney Int. 2024. PMID: 39218393
Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes.
Neuen BL, Ostrominski JW, Claggett B, Beldhuis IE, Chatur S, McCausland FR, Badve SV, Arnott C, Heerspink HJL, Jun M, Falster M, de Oliveira Costa J, Pollock C, Jardine MJ, Mahaffey KW, Perkovic V, Solomon SD, Vaduganathan M. Neuen BL, et al. Among authors: heerspink hjl. J Am Coll Cardiol. 2024 Aug 26:S0735-1097(24)08155-5. doi: 10.1016/j.jacc.2024.08.006. Online ahead of print. J Am Coll Cardiol. 2024. PMID: 39217558 No abstract available.
A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.
Miyamoto S, Heerspink HJL, de Zeeuw D, Sakamoto K, Yoshida M, Toyoda M, Suzuki D, Hatanaka T, Nakamura T, Kamei S, Murao S, Hida K, Ando S, Akai H, Takahashi Y, Kitada M, Sugano H, Nunoue T, Nakamura A, Sasaki M, Nakatou T, Fujimoto K, Kawanami D, Wada T, Miyatake N, Kuramoto H, Shikata K; CANPIONE study Investigators. Miyamoto S, et al. Among authors: heerspink hjl. Kidney Int. 2024 Aug 30:S0085-2538(24)00625-2. doi: 10.1016/j.kint.2024.08.019. Online ahead of print. Kidney Int. 2024. PMID: 39216659 Free article.
455 results